Benzinga

JANUARY 5, 2024

This is an exciting day as we officially bring together the innovative multi-omic technologies and incredible talent of Standard BioTools and SomaLogic to create one company that is a diversified leader in life sciences tools," said Michael Egholm, PhD, President and Chief Executive Officer of Standard BioTools.

Capital Structure 40

Capital Structure Technology Marketability 40

Benzinga

MARCH 1, 2024

"The proceeds from the sale of our Tower business will provide Shentel with additional growth capital to support the planned expansion of our Glo Fiber line of business to approximately 600,000 homes and business passings by the end of 2026.

Capital Structure 45

Capital Structure EBITDA Finance Technology 45

Benzinga

DECEMBER 21, 2023

We expect this will deliver $300 million in combined revenue by 2026. Accelerates our path to profitability through enhanced operating leverage and an anticipated $80 million in run-rate cost synergies by 2026. The capital structure of the combined company is not risky.

Capital Structure 40

Capital Structure Dividends Equity Marketability 40

Benzinga

OCTOBER 4, 2023

NASDAQ: LAB ), driven by a bold purpose – Unleashing tools to accelerate breakthroughs in human health – and SomaLogic (NASDAQ: SLGC ), a leader in data-driven proteomics technology, today announced that they have entered into a definitive agreement to combine in an all-stock merger. and BOULDER, Colo.,

Technology 40

Technology Capital Structure Equity Marketability 40